1. Home
  2. HOWL vs ASMB Comparison

HOWL vs ASMB Comparison

Compare HOWL & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOWL
  • ASMB
  • Stock Information
  • Founded
  • HOWL 2017
  • ASMB 2005
  • Country
  • HOWL United States
  • ASMB United States
  • Employees
  • HOWL N/A
  • ASMB N/A
  • Industry
  • HOWL Biotechnology: Pharmaceutical Preparations
  • ASMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOWL Health Care
  • ASMB Health Care
  • Exchange
  • HOWL Nasdaq
  • ASMB Nasdaq
  • Market Cap
  • HOWL 87.4M
  • ASMB 92.1M
  • IPO Year
  • HOWL 2021
  • ASMB 2010
  • Fundamental
  • Price
  • HOWL $1.36
  • ASMB $13.42
  • Analyst Decision
  • HOWL Strong Buy
  • ASMB Buy
  • Analyst Count
  • HOWL 2
  • ASMB 2
  • Target Price
  • HOWL $9.50
  • ASMB $35.00
  • AVG Volume (30 Days)
  • HOWL 269.3K
  • ASMB 22.9K
  • Earning Date
  • HOWL 03-06-2025
  • ASMB 03-27-2025
  • Dividend Yield
  • HOWL N/A
  • ASMB N/A
  • EPS Growth
  • HOWL N/A
  • ASMB N/A
  • EPS
  • HOWL N/A
  • ASMB N/A
  • Revenue
  • HOWL $3,386,000.00
  • ASMB $28,326,000.00
  • Revenue This Year
  • HOWL N/A
  • ASMB $282.16
  • Revenue Next Year
  • HOWL $34.17
  • ASMB N/A
  • P/E Ratio
  • HOWL N/A
  • ASMB N/A
  • Revenue Growth
  • HOWL N/A
  • ASMB N/A
  • 52 Week Low
  • HOWL $1.26
  • ASMB $11.01
  • 52 Week High
  • HOWL $8.19
  • ASMB $19.93
  • Technical
  • Relative Strength Index (RSI)
  • HOWL 41.40
  • ASMB 40.25
  • Support Level
  • HOWL $1.26
  • ASMB $13.60
  • Resistance Level
  • HOWL $1.45
  • ASMB $14.25
  • Average True Range (ATR)
  • HOWL 0.09
  • ASMB 0.58
  • MACD
  • HOWL 0.02
  • ASMB -0.05
  • Stochastic Oscillator
  • HOWL 45.45
  • ASMB 5.93

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: